23-Apr-2021 | Facts and Factors
Findings from Facts and Factors report “Aggregometer Market By Type (Flow-Cytometry, Impedance Whole Blood Aggregometry, Lumi-Aggregometry, Light Transmission Aggregometry (LTA), and Others), By Application (Research Applications and Clinical Applications), and By End-Use (Research and Academic Institutes, Standalone Hospitals, Blood Banks, Diagnostic Laboratories, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global aggregometer market in 2019 was approximately USD 360 Million. The market is anticipated to grow at a CAGR of 6.7% and is anticipated to reach around USD 570 Million by 2026.
Since the twentieth century, the aggregometer, also known as a platelet aggregation method, has been used to calculate the role of platelets. Platelets are involved in blood coagulation and wound healing, which is achieved by a process known as platelet aggregation. In thrombotic, vascular ischemic, and hemorrhagic diseases, platelets are thought to play a role. As a result, anti-platelet therapy (APT) has become the gold standard for multiple cardiovascular diseases, leading to the development of new antiplatelet drugs as well as a number of platelet function tests.
Browse the full “Aggregometer Market By Type (Iimpedance Whole Blood Aggregometry, Light Transmission Aggregometry (LTA), Lumi-Aggregometry, Flow-Cytometry, and Others), By Application (Clinical Applications, and Research Applications), By End-Use (Standalone Hospitals, Diagnostic Laboratories, Research and Academic Institutes, Blood Banks, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/aggregometer-market.
The aggregometer market is segmented in terms of type, application, and end-use. Based on the product type, the market is divided into flow-cytometry, impedance whole blood aggregometry, lumi-aggregometry, light transmission aggregometry (LTA), and others. LTA is the gold standard approach for measuring platelet function among these. LTA is the most often used screening procedure for platelet activity abnormalities and antiplatelet therapy control. Based on the application, the market is split into research applications and clinical applications. The segment of clinical applications is anticipated to hold the largest market share as for decades, the aggregometer has become the most widely used equipment in clinical laboratories as a powerful analytical instrument. It can be used to assess the inhibitory and excitatory effects of drugs on platelets and to measure the efficacy of antiplatelet therapy drugs in subjects. It's also used in in vitro experiments to assess platelet activity in human samples before they're put into clinical trials. Aggregometers with several test modes are available on the market. The number of individual measurements that can be run at the same time is equivalent to the total range of systems in an aggregometer. Any of the aggregometer on the market do not only detect platelet function but also diagnose the sample for von Willebrand's disease. On the basis of end-user analysis, the market is bifurcated into research and academic institutes, standalone hospitals, blood banks, diagnostic laboratories, and others. The standalone hospitals' segment had the largest market share and is projected to continue to do so throughout the estimated period. This high percentage is attributed to an increase in the number of hospitals in developing countries, the public and private investments in healthcare infrastructure growth and modernization, and increased use of platelet function testing in pre-and perioperative hemostasis and transfusion medicine. In the hospital's clinical laboratory, screening procedures such as Visco-elastometry are used to assess the severity of a blood clot. Furthermore, rising surgeon understanding of the benefits of platelet function testing and technical advances in platelet aggregation technologies, the patient use of innovative platelet aggregation devices, and rising surgical procedures are both driving demand for these devices in hospitals.
The global burden of cardiac mortality is rising due to an increase in the prevalence of heart attacks such as stroke and coronary heart disease, which has fueled the development of the aggregometer industry. Cardiovascular disease, for example, is identified as the underlying cause of death in the American Heart Association Research Report 2018, accounting for almost 836,546 deaths in the United States. This equates to nearly one in every three deaths in the world. Every day, almost 2,300 Americans die from cardiovascular disease, which equates to one death every 38 seconds. The dramatic growth in the number of people diagnosed with heart diseases fuels the market over the projected timeframe by increasing the use of aggregometer to research platelet aggregation worldwide.
The most effective method for diagnosing platelet defects is light transmission aggregometry (LTA). Furthermore, LTA necessitates a broad sampling volume, and analytical variables have an effect on LTA effects. As a result of both of these influences in conventional aggregometry, aggregometry techniques have developed and advanced, and are now commonly used in the sector. As a result, both of these innovations have been shown to increase penetration rates, thus aiding business development. Furthermore, trained technicians who can standardize, use, and modify procedures are needed for the commercial implementation of emerging technology used in care, research and development, and diagnosis. Any improvement in technique necessitates the use of professional technicians. As a result of a scarcity of qualified specialists to manage emerging technology or products, the market is expected to face growth challenges during the forecast era.
Top Market Players
Some of the key players in the market are Bio/Data Corporation, Siemens Healthineers AG, Chronolog Corporation, Sysmex Corporation, Helena Laboratories, Tem Group, Perfusion, WerfenLife, S.A., Hart Biologicals, Drucker Diagnostics, Alpha Laboratories, Haemonetics Corporation, Instrumentation Laboratory, F. Hoffmann-La Roche Ltd, Biola, and Others. The majority of these businesses are based in the United States and Europe. To maintain and grow their market share, these companies are aggressively competing through strategic mergers and acquisitions, product advancements, and the introduction of new and creative products. For example, the US FDA (Food and Drug Administration) approved Haemonetics Corporation's TEG 6s Hemostasis System, a coagulation analyzer, in May 2019. It's used to check for blood clotting. As a result of the above reasons, the demand in this segment is projected to expand at a healthy rate over the forecast period.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 360 Million |
Projected Market Size in 2026 |
USD 570 Million |
CAGR Growth Rate |
6.7% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Bio/Data Corporation, Chronolog Corporation, Helena Laboratories, Perfusion, Hart Biologicals, Alpha Laboratories, Instrumentation Laboratory, Biola, WerfenLife, S.A.F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Tem Group, Sysmex Corporation, Haemonetics Corporation, Drucker Diagnostics, and Others. These key players in order to obtain a reputed position in the global market have implemented several strategies such as signing agreements, bonds, contracts, partnerships, joint ventures, new product launches, collaborations, and mergers & acquisitions. |
Key Segment |
By Type, By Application, By Application, By End-Use, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
This report segments the aggregometer market as follows:
Global Aggregometer Market: By Type Segmentation Analysis:
- Flow-Cytometry
- Impedance Whole Blood Aggregometry
- Lumi-Aggregometry
- Light Transmission Aggregometry (LTA)
- Others
Global Aggregometer Market: By Application Segmentation Analysis
- Research Applications
- Clinical Applications
Global Aggregometer Market: By End-Use Segmentation Analysis
- Research and Academic Institutes
- Standalone Hospitals
- Blood Banks
- Diagnostic Laboratories
- Others
Global Aggregometer Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
